A 2026 study published in The Lancet suggests that tirzepatide, a dual GLP-1 and GIP receptor agonist already approved for treatment of diabetes and obesity, could be an effective tool for fighting alcohol use disorder (AUD).
Jennifer Sweenie is an author based in New York, specializing in health reporting. With a focus on functional nutrition, diet and wellness programs, she explores the intersections of health, alternative medicine, and the impact of natural, whole foods. Jennifer's work has been featured in Tasting Table, Food Republic, The Epoch Times, Medical University of South Carolina, and SUCCESS Magazine.








